Gray Market Peptides: So Much Hype, So Little Data The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica